Beam Therapeutics Inc. Research and Development Expense
Beam Therapeutics Inc. (BEAM) reported Research and Development Expense of $95.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Beam Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $95.10M, a 6.55% decline year-over-year.
- Beam Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $104.52M, a 5.78% increase year-over-year.
- Beam Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $99.28M, a 2.14% decline year-over-year.
- Beam Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $109.77M, a 16.46% increase year-over-year.
- Beam Therapeutics Inc. research and development expense for fiscal 2025 was $409.62M, a 11.44% increase from fiscal 2024.
- Beam Therapeutics Inc. research and development expense for fiscal 2024 was $367.56M, a 15.96% decline from fiscal 2023.
- Beam Therapeutics Inc. research and development expense for fiscal 2023 was $437.38M, a 40.37% increase from fiscal 2022.
- Beam Therapeutics Inc. research and development expense for fiscal 2022 was $311.59M, a 19.50% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.10M 10-Q · filed 2026-08-04 | $199.62M 10-Q · filed 2026-08-04 | $298.89M derived: sum of 3 quarters · filed 2026-08-04 | $408.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $104.52M 10-Q · filed 2026-05-07 | $203.80M derived: sum of 2 quarters · filed 2026-05-07 | $313.57M derived: sum of 3 quarters · filed 2026-05-07 | $415.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $99.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $209.04M derived: sum of 2 quarters · filed 2026-02-24 | $310.80M derived: sum of 3 quarters · filed 2026-08-04 | $409.62M 10-K · filed 2026-02-24 |
| 2025-09-30 | $109.77M 10-Q · filed 2025-11-04 | $211.53M derived: sum of 2 quarters · filed 2026-08-04 | $310.34M 10-Q · filed 2025-11-04 | $411.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $101.76M 10-Q · filed 2026-08-04 | $200.57M 10-Q · filed 2026-08-04 | $302.02M derived: sum of 3 quarters · filed 2026-08-04 | $396.28M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $98.82M 10-Q · filed 2026-05-07 | $200.26M derived: sum of 2 quarters · filed 2026-05-07 | $294.52M derived: sum of 3 quarters · filed 2026-05-07 | $381.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $101.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $195.70M derived: sum of 2 quarters · filed 2026-02-24 | $282.74M derived: sum of 3 quarters · filed 2026-02-24 | $367.56M 10-K · filed 2026-02-24 |
| 2024-09-30 | $94.26M 10-Q · filed 2025-11-04 | $181.30M derived: sum of 2 quarters · filed 2025-11-04 | $266.12M 10-Q · filed 2025-11-04 | $406.19M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $87.04M 10-Q · filed 2025-08-05 | $171.86M 10-Q · filed 2025-08-05 | $311.94M derived: sum of 3 quarters · filed 2026-02-24 | $411.99M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $84.82M 10-Q · filed 2025-05-06 | $224.90M derived: sum of 2 quarters · filed 2026-02-24 | $324.94M derived: sum of 3 quarters · filed 2026-02-24 | $422.55M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $140.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $240.13M derived: sum of 2 quarters · filed 2026-02-24 | $337.74M derived: sum of 3 quarters · filed 2026-02-24 | $437.38M 10-K · filed 2026-02-24 |
| 2023-09-30 | $100.05M 10-Q · filed 2024-11-05 | $197.66M derived: sum of 2 quarters · filed 2024-11-05 | $297.30M 10-Q · filed 2024-11-05 | $383.64M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $97.61M 10-Q · filed 2024-08-06 | $197.25M 10-Q · filed 2024-08-06 | $283.60M derived: sum of 3 quarters · filed 2025-02-25 | $368.88M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $99.65M 10-Q · filed 2024-05-07 | $185.99M derived: sum of 2 quarters · filed 2025-02-25 | $271.27M derived: sum of 3 quarters · filed 2025-02-25 | $345.83M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $86.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $171.63M derived: sum of 2 quarters · filed 2025-02-25 | $246.18M derived: sum of 3 quarters · filed 2025-02-25 | $311.59M 10-K · filed 2025-02-25 |
| 2022-09-30 | $85.29M 10-Q · filed 2023-11-08 | $159.84M derived: sum of 2 quarters · filed 2023-11-08 | $225.25M 10-Q · filed 2023-11-08 | $322.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $74.56M 10-Q · filed 2023-08-08 | $139.97M 10-Q · filed 2023-08-08 | $236.75M derived: sum of 3 quarters · filed 2024-02-27 | $291.37M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $65.41M 10-Q · filed 2023-05-10 | $162.19M derived: sum of 2 quarters · filed 2024-02-27 | $216.81M derived: sum of 3 quarters · filed 2024-02-27 | $262.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $96.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $151.40M derived: sum of 2 quarters · filed 2024-02-27 | $196.98M derived: sum of 3 quarters · filed 2024-02-27 | $387.09M 10-K · filed 2024-02-27 |
| 2021-09-30 | $54.62M 10-Q · filed 2022-11-07 | $100.20M derived: sum of 2 quarters · filed 2022-11-07 | $290.31M 10-Q · filed 2022-11-07 | $322.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $45.58M 10-Q · filed 2022-08-09 | $235.68M 10-Q · filed 2022-08-09 | $268.13M derived: sum of 3 quarters · filed 2023-02-28 | $297.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $190.11M 10-Q · filed 2022-05-09 | $222.56M derived: sum of 2 quarters · filed 2023-02-28 | $252.38M derived: sum of 3 quarters · filed 2023-02-28 | $271.74M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $32.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $62.28M derived: sum of 2 quarters · filed 2023-02-28 | $81.63M derived: sum of 3 quarters · filed 2023-02-28 | $103.18M 10-K · filed 2023-02-28 |
| 2020-09-30 | $29.82M 10-Q · filed 2021-11-08 | $49.18M derived: sum of 2 quarters · filed 2021-11-08 | $70.73M 10-Q · filed 2021-11-08 | $90.94M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $19.35M 10-Q · filed 2021-08-10 | $40.90M 10-Q · filed 2021-08-10 | $61.12M derived: sum of 3 quarters · filed 2022-02-28 | $73.66M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $21.55M 10-Q · filed 2021-05-11 | $41.77M derived: sum of 2 quarters · filed 2022-02-28 | $54.31M derived: sum of 3 quarters · filed 2022-02-28 | $66.99M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $20.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $32.76M derived: sum of 2 quarters · filed 2022-02-28 | $45.44M derived: sum of 3 quarters · filed 2022-02-28 | $54.62M 10-K · filed 2022-02-28 |
| 2019-09-30 | $12.54M 10-Q · filed 2020-11-10 | $25.22M derived: sum of 2 quarters · filed 2020-11-10 | $34.40M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $12.68M 10-Q · filed 2020-08-12 | $21.86M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $9.18M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |